1. Home
  2. TECX vs DCTH Comparison

TECX vs DCTH Comparison

Compare TECX & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tectonic Therapeutic Inc. Common Stock

TECX

Tectonic Therapeutic Inc. Common Stock

HOLD

Current Price

$20.98

Market Cap

359.0M

Sector

N/A

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$10.02

Market Cap

289.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TECX
DCTH
Founded
2019
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
359.0M
289.2M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
TECX
DCTH
Price
$20.98
$10.02
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
5
Target Price
$81.20
$22.60
AVG Volume (30 Days)
407.9K
816.4K
Earning Date
11-06-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.03
Revenue
N/A
$79,603,000.00
Revenue This Year
N/A
$131.97
Revenue Next Year
N/A
$38.84
P/E Ratio
N/A
$292.41
Revenue Growth
N/A
251.54
52 Week Low
$13.70
$8.12
52 Week High
$61.07
$18.23

Technical Indicators

Market Signals
Indicator
TECX
DCTH
Relative Strength Index (RSI) 59.16 58.95
Support Level $18.60 $9.25
Resistance Level $22.00 $9.80
Average True Range (ATR) 1.72 0.48
MACD 0.09 0.20
Stochastic Oscillator 78.88 95.00

Price Performance

Historical Comparison
TECX
DCTH

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: